Welcome to NewPressRelease.com a free press release service. Publishing press releases for Public Relations never been easier. Just register (it's free and it takes less then a 1 minute) then use Submit Press Release. Our services aim to help you reach journalists and to improve visibility in search engine listings, so you can get the most publicity possible.

Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016

Health and Fitness

(Free Press Release) Bharatbook added a new report on Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 which gives comprehensive and effective methods to tackle atrial fibrillation.

Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016


      

Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 (NewPressRelease) This is an essential source of information and analysis on the global atrial fibrillation market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atrial fibrillation sector. ( http://www.bharatbook.com/detail.asp?id=132168&rt=Atrial-Fibrillation-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )

The Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016The atrial fibrillation (AF) market is currently on the brink of rapid expansion due to the expected launch of novel products between 2010 and 2016 with new first-in-class molecules likely to replace the age-old generics which have been dominating the market, chiefly due to their low costs and a lack of suitable alternatives. The latest entrant into the market was Multaq in 2009. It was launched after the loss of patent protection for Sanofi-Aventis's previous anti-arrythmic drug, Cordarone (amiodarone) in the US in 2002. The presently marketed products have numerous adverse events and associated toxic side-effects. It would, therefore, be sufficient for newer entrants to demonstrate a superior efficacy and safety profile in order to capture value in the market from the currently used generic drugs. In-depth analysis reveals that Stedicor is likely to dominate the future AF market followed by Kynapid, given that there were numerous safety related concerns over Multaq in patients.

 Nevertheless, the market is all set to witness a definite paradigm shift in the treatment of atrial fibrillation with the entry of new products that would command higher prices owing to their clinical superiority. Increase in the treatment seeking population, prescription rates and an increase in the ageing global population are considered to be important drivers for this market. A high projected growth rate is primarily attributable to the potentially strong late stage pipeline. Availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the atrial fibrillation market.Atrial Fibrillation Market Set to Witness A Race for the Next Blockbuster ProductThe current competition in the atrial fibrillation market to be weak as the market is mainly governed by generics that have comparable safety and efficacy profiles. This apart, major revenue for this market are generated by anticoagulants, which are prescribed in addition to anti-arrythmics to achieve a superior rate of rhythm control in patients. The anticoagulants market is in itself set to witness a remarkable growth rate with the approval of newer oral anticoagulants. The entry of these newer classes of drugs will undoubtedly accelerate the growth of the atrial fibrillation market also and annul the use of warfarins and other vitamin K antagonists.

This would, in turn, start a race among the new entrants to capture value in the market and kick-start a phase of unprecedented growth. Procter and Gamble’s (P & G’s) Stedicor is expected to lead sales in the atrial fibrillation market in the next few years. However, other products, such as Multaq, Pradaxa, and Xarelto are likely to give strong competition to Stedicor. The entry of newer atrial fibrillation agents would propel the growth of the market forward, with an estimated quadrupling of the current market revenues.New Entrants Are likely to Bring A Paradigm Shift in Conventional treatment options for Atrial FibrillationThe presently available treatment options are moderately successful in meeting the market demand. Newer anti-arrhythmic drugs, which block multiple channels or have specificity for the atrial myocardium, are believed to present a more favorable risk-benefit ratio than traditional anti-arrhythmic drugs. As a wider perspective is likely to develop in the future among physicians and cardiologists, due to the entry of novel drugs in the market, the genesis of a new and refined atrial fibrillation drug therapy is predicted to emerge, with gap junction modulators, ion channel blockers and effective oral anti-coagulation therapies leading the way. These may offer more comprehensive and effective methods to tackle atrial fibrillation. A paradigm shift is therefore predicted in this market.

To know more and to buy a copy of your report feel free to visit :

http://www.bharatbook.com/detail.asp?id=132168&rt=Atrial-Fibrillation-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Or Contact us at :Bharat Book Bureau

Tel: +91 22 27578668

Fax: +91 22 27579131

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 Website: www.bharatbook.com

Share |



Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016

Source: Press Release

---------------------------

Disclaimer

If you have any questions regarding information in this press release, please contact the person listed as the Author or use the contact informations published in the press release. Please do not attempt to contact NewPressRelease.com. We are unable to assist you with any information regarding this release. NewPressRelease.com disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.

Latest News


Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Warning: Creating default object from empty value in /home/freeim/newpressrelease.com/modules/mod_latestnews/helper.php on line 109

Related Items

All press release information on this site, including free press releases, is solely based on what our users submit. NewPressRelease.com disclaims that any right and responsibility for the information goes to the user who submit the press release. Some press release may be confusing without additional explanation. You should contact the provider with any questions about the information presented. In case some press release damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.


Copyright © 2008 - 2014 Free Press Release by NewPressRelease.com